State Street Corp Cuts Stock Position in Edwards Lifesciences Corporation $EW

State Street Corp lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,634,378 shares of the medical research company’s stock after selling 149,084 shares during the quarter. State Street Corp owned about 4.37% of Edwards Lifesciences worth $2,004,865,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Daiwa Securities Group Inc. grew its holdings in Edwards Lifesciences by 21.2% in the second quarter. Daiwa Securities Group Inc. now owns 139,934 shares of the medical research company’s stock worth $10,944,000 after purchasing an additional 24,475 shares during the last quarter. L2 Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $204,000. WINTON GROUP Ltd boosted its position in shares of Edwards Lifesciences by 139.9% in the 2nd quarter. WINTON GROUP Ltd now owns 74,078 shares of the medical research company’s stock worth $5,794,000 after purchasing an additional 43,197 shares in the last quarter. Natixis boosted its position in shares of Edwards Lifesciences by 36.5% in the 2nd quarter. Natixis now owns 314,383 shares of the medical research company’s stock worth $24,588,000 after purchasing an additional 84,139 shares in the last quarter. Finally, Ossiam grew its stake in Edwards Lifesciences by 49.1% during the 2nd quarter. Ossiam now owns 56,169 shares of the medical research company’s stock worth $4,393,000 after buying an additional 18,492 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $83.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, December 5th. Barclays reiterated an “overweight” rating and issued a $103.00 target price (up from $99.00) on shares of Edwards Lifesciences in a research note on Monday. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a research report on Monday, November 3rd. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $93.09.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $83.97 on Thursday. The company has a 50 day simple moving average of $81.34 and a two-hundred day simple moving average of $78.92. The stock has a market cap of $48.73 billion, a price-to-earnings ratio of 36.19, a PEG ratio of 3.74 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company posted $0.67 earnings per share. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 33,060 shares of company stock valued at $2,765,292 over the last quarter. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.